Different drug-resistant influenza A(H3N2) variants in two immunocompromised patients treated with oseltamivir during the 2011-2012 influenza season in Italy

被引:15
作者
Piralla, A. [1 ]
Gozalo-Margueello, M. [2 ]
Fiorina, L. [1 ]
Rovida, F. [1 ]
Muzzi, A. [3 ]
Colombo, A. A. [4 ]
Alessandrino, P. E. [4 ]
Baldanti, F. [1 ]
机构
[1] Fdn IRCCS Policlin San Matteo, SS Virol Mol, SC Virol & Microbiol, I-27100 Pavia, Italy
[2] Hosp U Marques de Valdecilla IFIMAV, Santander, Spain
[3] Fdn IRCCS Policlin San Matteo, SC Direz Med Presidio, I-27100 Pavia, Italy
[4] Fdn IRCCS Policlin San Matteo, Unita Trapianto Midollo, I-27100 Pavia, Italy
关键词
Influenza; R292K; E119V; N294S; Del247-250; Oseltamivir treated patients; NEURAMINIDASE ACTIVE-SITE; FRAMEWORK MUTATIONS; VIRUS; INHIBITORS; DESIGN; E119V;
D O I
10.1016/j.jcv.2013.06.003
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Background: Monitoring the emergence of drug-resistant influenza variants is crucial in influenza surveillance programs. Objectives: Influenza A kinetics and the emergence of drug-resistant strains in hospitalized patients treated with oseltamivir were investigated. Study design: Sequential samples from oseltamivir-treated and -untreated hospitalized patients in the period November 2011 through April 2012 were analyzed. NA gene was sequenced in samples from oseltamivir treated patients. Clonal analysis of the viral population was performed in patients unresponsive to treatment. Viral kinetics was determined in 24 (14 immunocompromised and 10 immunocompetent) A(H3N2)-positive patients treated and 24 (10 immunocompromised and 14 immunocompetent) untreated patients. Results: Viral shedding was significantly reduced in treated vs untreated immunocompromised patients (7 vs 22 days, p<0.05, respectively). Viral load decreased significantly in immunocompromised and immunocompetent treated patients as compared with immunocompromised and immunocompetent untreated patients (0.73 and 0.93 vs 0.47 and 0.45 log(10)/day, p<0.05). In two (8.3%) treated patients with prolonged virus shedding, the oseltamivir resistance R292K mutation was revealed. In these patients, clonal analysis of the virus population showed the presence of additional oseltamivir-resistant mutants (E119V, N294S and deletion Del247-250). Conclusions: Oseltamivir resistance is reported for the first time in A(H3N2) virus strains during the 2011-2012 influenza season. Different drug-resistant viruses emerged in hospitalized immunocompromised patients showing prolonged virus shedding. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:132 / 137
页数:6
相关论文
共 32 条
[1]  
Abed Y, 2006, ANTIVIR THER, V11, P971
[2]   A Novel Neuraminidase Deletion Mutation Conferring Resistance to Oseltamivir in Clinical Influenza A/H3N2 Virus [J].
Abed, Yacine ;
Baz, Mariana ;
Boivin, Guy .
JOURNAL OF INFECTIOUS DISEASES, 2009, 199 (02) :180-183
[3]  
[Anonymous], 2009, INFL H1N1 VIR RES OS
[4]   Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child [J].
Baz, Mariana ;
Abed, Yacine ;
McDonald, Jane ;
Boivin, Guy .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1555-1561
[5]   First case in Italy of acquired resistance to oseltamivir in an immunocompromised patient with influenza A/H1N1v infection [J].
Campanini, Giulia ;
Piralla, Antonio ;
Rovida, Francesca ;
Puzelli, Simona ;
Facchini, Marzia ;
Locatelli, Franco ;
Minoli, Lorenzo ;
Percivalle, Elena ;
Donatelli, Isabella ;
Baldanti, Fausto .
JOURNAL OF CLINICAL VIROLOGY, 2010, 48 (03) :220-222
[6]   STRUCTURE OF THE CATALYTIC AND ANTIGENIC SITES IN INFLUENZA-VIRUS NEURAMINIDASE [J].
COLMAN, PM ;
VARGHESE, JN ;
LAVER, WG .
NATURE, 1983, 303 (5912) :41-44
[7]  
EuropeanCentre forDisease Prevention andControl (ECDC), 2012, INFL VIR CHAR SUMM E
[8]   Mutations of neuraminidase implicated in neuraminidase inhibitors resistance [J].
Ferraris, Olivier ;
Lina, Bruno .
JOURNAL OF CLINICAL VIROLOGY, 2008, 41 (01) :13-19
[9]  
Fiore Anthony E., 2011, Morbidity and Mortality Weekly Report, V60, P1
[10]  
Grohskopf Lisa, 2011, Morbidity and Mortality Weekly Report, V60, P1128